Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia

Marilyn Ader, W. Timothy Garvey, Lawrence S. Phillips, Charles Nemeroff, Georges Gharabawi, Ramy Mahmoud, Andrew Greenspan, Sally A. Berry, Dominique Musselman, Jacqueline Morein, Young Zhu, Lian Mao, Richard N. Bergman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Atypical antipsychotics induce weight gain and are linked to increased diabetes risk, but their relative impact on factors that elevate disease risk are unknown. Methods: We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia. At baseline and weeks 6 and 24, we quantified: (1) total adiposity by DEXA, (2) visceral adiposity by abdominal CT, and (3) insulin sensitivity (SI) and (4) pancreatic function ("disposition index", DI) by intravenous glucose tolerance test. Results: At baseline, groups (risperidone: n = 28; olanzapine: n = 31) were overweight or obese by body mass index (risperidone: 28.4 ± 5.4, olanzapine: 30.6 ± 7.0 kg/m2). Both drugs induced weight gain (p < 0.004). Total adiposity was increased by olanzapine at 6 weeks (p = 0.0006) and by both treatments at 24 weeks (p < 0.003). Visceral adiposity was increased by olanzapine and risperidone by 24 weeks (p < 0.003). SI did not deteriorate appreciably, although a downward trend was observed with risperidone. Given known ethnic differences in adiposity and SI, we performed secondary analysis in African American and Hispanic subjects. In this subset, olanzapine expanded both total and visceral adiposity (p < 0.02); no increase was observed with risperidone. There were modest downward trends for SI with both treatments. By week 24, olanzapine-treated subjects exhibited diminished DI (p = 0.033), indicating inadequate pancreatic compensation for insulin resistance. Conclusions: This is the first prospective study in psychiatric patients that quantified antipsychotic effects on the multiple metabolic processes that increase diabetes risk. Results indicate that ethnic minorities may have greater susceptibility to antipsychotic-induced glucoregulatory complications.

Original languageEnglish
Pages (from-to)1076-1085
Number of pages10
JournalJournal of Psychiatric Research
Volume42
Issue number13
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

olanzapine
Risperidone
Adiposity
Antipsychotic Agents
Schizophrenia
Therapeutics
Weight Gain
Insulin Resistance
Glucose Tolerance Test
Hispanic Americans
Double-Blind Method
African Americans
Psychiatry
Body Mass Index

Keywords

  • Diabetes
  • Minorities
  • Olanzapine
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. / Ader, Marilyn; Garvey, W. Timothy; Phillips, Lawrence S.; Nemeroff, Charles; Gharabawi, Georges; Mahmoud, Ramy; Greenspan, Andrew; Berry, Sally A.; Musselman, Dominique; Morein, Jacqueline; Zhu, Young; Mao, Lian; Bergman, Richard N.

In: Journal of Psychiatric Research, Vol. 42, No. 13, 01.10.2008, p. 1076-1085.

Research output: Contribution to journalArticle

Ader, M, Garvey, WT, Phillips, LS, Nemeroff, C, Gharabawi, G, Mahmoud, R, Greenspan, A, Berry, SA, Musselman, D, Morein, J, Zhu, Y, Mao, L & Bergman, RN 2008, 'Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia', Journal of Psychiatric Research, vol. 42, no. 13, pp. 1076-1085. https://doi.org/10.1016/j.jpsychires.2008.01.004
Ader, Marilyn ; Garvey, W. Timothy ; Phillips, Lawrence S. ; Nemeroff, Charles ; Gharabawi, Georges ; Mahmoud, Ramy ; Greenspan, Andrew ; Berry, Sally A. ; Musselman, Dominique ; Morein, Jacqueline ; Zhu, Young ; Mao, Lian ; Bergman, Richard N. / Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. In: Journal of Psychiatric Research. 2008 ; Vol. 42, No. 13. pp. 1076-1085.
@article{2fa0573425c7486fae70d2d1263829fa,
title = "Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia",
abstract = "Objective: Atypical antipsychotics induce weight gain and are linked to increased diabetes risk, but their relative impact on factors that elevate disease risk are unknown. Methods: We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia. At baseline and weeks 6 and 24, we quantified: (1) total adiposity by DEXA, (2) visceral adiposity by abdominal CT, and (3) insulin sensitivity (SI) and (4) pancreatic function ({"}disposition index{"}, DI) by intravenous glucose tolerance test. Results: At baseline, groups (risperidone: n = 28; olanzapine: n = 31) were overweight or obese by body mass index (risperidone: 28.4 ± 5.4, olanzapine: 30.6 ± 7.0 kg/m2). Both drugs induced weight gain (p < 0.004). Total adiposity was increased by olanzapine at 6 weeks (p = 0.0006) and by both treatments at 24 weeks (p < 0.003). Visceral adiposity was increased by olanzapine and risperidone by 24 weeks (p < 0.003). SI did not deteriorate appreciably, although a downward trend was observed with risperidone. Given known ethnic differences in adiposity and SI, we performed secondary analysis in African American and Hispanic subjects. In this subset, olanzapine expanded both total and visceral adiposity (p < 0.02); no increase was observed with risperidone. There were modest downward trends for SI with both treatments. By week 24, olanzapine-treated subjects exhibited diminished DI (p = 0.033), indicating inadequate pancreatic compensation for insulin resistance. Conclusions: This is the first prospective study in psychiatric patients that quantified antipsychotic effects on the multiple metabolic processes that increase diabetes risk. Results indicate that ethnic minorities may have greater susceptibility to antipsychotic-induced glucoregulatory complications.",
keywords = "Diabetes, Minorities, Olanzapine, Risperidone, Schizophrenia",
author = "Marilyn Ader and Garvey, {W. Timothy} and Phillips, {Lawrence S.} and Charles Nemeroff and Georges Gharabawi and Ramy Mahmoud and Andrew Greenspan and Berry, {Sally A.} and Dominique Musselman and Jacqueline Morein and Young Zhu and Lian Mao and Bergman, {Richard N.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.jpsychires.2008.01.004",
language = "English",
volume = "42",
pages = "1076--1085",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia

AU - Ader, Marilyn

AU - Garvey, W. Timothy

AU - Phillips, Lawrence S.

AU - Nemeroff, Charles

AU - Gharabawi, Georges

AU - Mahmoud, Ramy

AU - Greenspan, Andrew

AU - Berry, Sally A.

AU - Musselman, Dominique

AU - Morein, Jacqueline

AU - Zhu, Young

AU - Mao, Lian

AU - Bergman, Richard N.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objective: Atypical antipsychotics induce weight gain and are linked to increased diabetes risk, but their relative impact on factors that elevate disease risk are unknown. Methods: We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia. At baseline and weeks 6 and 24, we quantified: (1) total adiposity by DEXA, (2) visceral adiposity by abdominal CT, and (3) insulin sensitivity (SI) and (4) pancreatic function ("disposition index", DI) by intravenous glucose tolerance test. Results: At baseline, groups (risperidone: n = 28; olanzapine: n = 31) were overweight or obese by body mass index (risperidone: 28.4 ± 5.4, olanzapine: 30.6 ± 7.0 kg/m2). Both drugs induced weight gain (p < 0.004). Total adiposity was increased by olanzapine at 6 weeks (p = 0.0006) and by both treatments at 24 weeks (p < 0.003). Visceral adiposity was increased by olanzapine and risperidone by 24 weeks (p < 0.003). SI did not deteriorate appreciably, although a downward trend was observed with risperidone. Given known ethnic differences in adiposity and SI, we performed secondary analysis in African American and Hispanic subjects. In this subset, olanzapine expanded both total and visceral adiposity (p < 0.02); no increase was observed with risperidone. There were modest downward trends for SI with both treatments. By week 24, olanzapine-treated subjects exhibited diminished DI (p = 0.033), indicating inadequate pancreatic compensation for insulin resistance. Conclusions: This is the first prospective study in psychiatric patients that quantified antipsychotic effects on the multiple metabolic processes that increase diabetes risk. Results indicate that ethnic minorities may have greater susceptibility to antipsychotic-induced glucoregulatory complications.

AB - Objective: Atypical antipsychotics induce weight gain and are linked to increased diabetes risk, but their relative impact on factors that elevate disease risk are unknown. Methods: We performed a 6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia. At baseline and weeks 6 and 24, we quantified: (1) total adiposity by DEXA, (2) visceral adiposity by abdominal CT, and (3) insulin sensitivity (SI) and (4) pancreatic function ("disposition index", DI) by intravenous glucose tolerance test. Results: At baseline, groups (risperidone: n = 28; olanzapine: n = 31) were overweight or obese by body mass index (risperidone: 28.4 ± 5.4, olanzapine: 30.6 ± 7.0 kg/m2). Both drugs induced weight gain (p < 0.004). Total adiposity was increased by olanzapine at 6 weeks (p = 0.0006) and by both treatments at 24 weeks (p < 0.003). Visceral adiposity was increased by olanzapine and risperidone by 24 weeks (p < 0.003). SI did not deteriorate appreciably, although a downward trend was observed with risperidone. Given known ethnic differences in adiposity and SI, we performed secondary analysis in African American and Hispanic subjects. In this subset, olanzapine expanded both total and visceral adiposity (p < 0.02); no increase was observed with risperidone. There were modest downward trends for SI with both treatments. By week 24, olanzapine-treated subjects exhibited diminished DI (p = 0.033), indicating inadequate pancreatic compensation for insulin resistance. Conclusions: This is the first prospective study in psychiatric patients that quantified antipsychotic effects on the multiple metabolic processes that increase diabetes risk. Results indicate that ethnic minorities may have greater susceptibility to antipsychotic-induced glucoregulatory complications.

KW - Diabetes

KW - Minorities

KW - Olanzapine

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=50049096707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049096707&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2008.01.004

DO - 10.1016/j.jpsychires.2008.01.004

M3 - Article

C2 - 18295798

AN - SCOPUS:50049096707

VL - 42

SP - 1076

EP - 1085

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 13

ER -